Dendreon (DNDN) Q4 Revs Top Views
Tweet
Share
E-mailGet Alerts DNDN Hot Sheet
Price: $0.13 --0%
Financial Fact:
Selling, general and administrative: 34.3M
Today's EPS Names:
SUNE, NSLR, OCTV, More
Financial Fact:
Selling, general and administrative: 34.3M
Today's EPS Names:
SUNE, NSLR, OCTV, More
Join SI Premium – FREE
Dendreon Corporation (NASDAQ: DNDN) announced preliminary revenues for the fourth quarter ended December 31, 2012. Net product revenue for the quarter is expected to be approximately $85.5 million, which includes an approximate $3.8 million favorable adjustment to the Company’s chargebacks reserve due to a change in estimate. On a pro-forma basis, excluding this adjustment, revenue for the quarter is expected to be approximately $81.6 million, up 5% on a sequential basis.
(Street estimates call for Q4 revenue of $80.71 million.)
Continued strong performance in community accounts:
Community urology grew 25% overall quarter over quarter
Community oncology grew 4% overall quarter over quarter
Community accounts represent 71% of total sales, up from 58% in Q4 2011
Natural shift away from academic, which declined 9% quarter over quarter
Continued new physician interest in PROVENGE® (sipuleucel-T):
Added 61 net new accounts in the fourth quarter, bringing total number of infusing accounts to 802
"We have focused our commercial efforts on growing our community accounts, where we see the greatest long-term revenue opportunity. Having achieved our highest quarter ever for community sales, we believe that our community strategy is working,” said John H. Johnson, president, chairman and chief executive officer. “Our key account management teams, combined with improved sales execution and direct-to-patient initiatives, are contributing to the increased use of PROVENGE in community oncology and urology settings, a trend we saw beginning in the third quarter. We are pleased that physicians continue to recognize the importance of sequencing therapy options in advanced prostate cancer treatment and the key role PROVENGE can play as front-line therapy in mCRPC."
(Street estimates call for Q4 revenue of $80.71 million.)
Continued strong performance in community accounts:
Community urology grew 25% overall quarter over quarter
Community oncology grew 4% overall quarter over quarter
Community accounts represent 71% of total sales, up from 58% in Q4 2011
Natural shift away from academic, which declined 9% quarter over quarter
Continued new physician interest in PROVENGE® (sipuleucel-T):
Added 61 net new accounts in the fourth quarter, bringing total number of infusing accounts to 802
"We have focused our commercial efforts on growing our community accounts, where we see the greatest long-term revenue opportunity. Having achieved our highest quarter ever for community sales, we believe that our community strategy is working,” said John H. Johnson, president, chairman and chief executive officer. “Our key account management teams, combined with improved sales execution and direct-to-patient initiatives, are contributing to the increased use of PROVENGE in community oncology and urology settings, a trend we saw beginning in the third quarter. We are pleased that physicians continue to recognize the importance of sequencing therapy options in advanced prostate cancer treatment and the key role PROVENGE can play as front-line therapy in mCRPC."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Octave Intelligence plc (OCTV) Tops Q2 EPS by 4c ; Offers Guidance
- Super Micro Computer (SMCI) Tops Q4 EPS by 99c; offers guidance
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
Create E-mail Alert Related Categories
Guidance, Hot GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
